Living Cell trial shows implant success, neurological improvements

Living Cell trial shows implant success, neurological improvements
By Jonathan Underhill June 15 (BusinessDesk) - Living Cell Technologies, an ASX-listed biotech company with operations based in New Zealand, said results of a small preliminary trial of its NTCELL therapy aimed at neuro-degenerative diseases showed the four patients with Parkinson's disease tolerated implantation and showed some improvement. Living Cell shares soared about 17 percent to 7.7 Australian cents after results of the study were released to the ASX. They have gained 54 percent in the past 12 months. The trial was conducted by...